Intra-Cellular Therapies | 4:持股變動聲明-高管 Mates Sharon
Intra-Cellular Therapies | 144:擬議出售證券
Intra-Cellular Therapies | 144:擬議出售證券
Intra-Cellular Therapies | 8-K:重大事件
Intra-Cellular Therapies | 4:持股變動聲明-高管 Halstead Michael
Intra-Cellular Therapies | 144:擬議出售證券
Intra-Cellular Therapies | SC 13G/A:超過5%持股股東披露文件(修正)-FMR LLC(10.525%),Abigail P. Johnson(10.525%)
Intra-Cellular Therapies | SC 13G/A:超過5%持股股東披露文件(修正)-BlackRock, Inc.(5.9%)
Intra-Cellular Therapies | 8-K:重大事件
Intra-Cellular Therapies | 10-Q:2024財年三季報
Intra-Cellular Therapies | 8-K:細胞內療法公佈了2024年第三季度財務業績,提供了公司最新情況,並提高了2024年的CAPLYTA銷售指導
Intra-Cellular Therapies | SC 13G/A:超過5%持股股東披露文件(修正)-BlackRock, Inc.(5.9%)
Intra-Cellular Therapies | 4:持股變動聲明-董事 RIGGS RORY B
Intra-Cellular Therapies | SC 13G:超過5%持股股東披露文件-JPMORGAN CHASE & CO.(5.0%)
Intra-Cellular Therapies | 4:持股變動聲明-董事 RIGGS RORY B
Intra-Cellular Therapies | 144:擬議出售證券
Intra-Cellular Therapies | 4:持股變動聲明-高管 Mates Sharon
Intra-Cellular Therapies | 144:擬議出售證券
Intra-Cellular Therapies | 144:擬議出售證券
Intra-Cellular Therapies | 4:持股變動聲明-高管 Mates Sharon
暫無數據